GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » Current Accrued Expense

Pentixapharm Holding AG (XTER:PTP) Current Accrued Expense : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pentixapharm Holding AG Current Accrued Expense?

Pentixapharm Holding AG's Current Accrued Expense for the quarter that ended in Dec. 2024 was €0.00 Mil.


Pentixapharm Holding AG Current Accrued Expense Historical Data

The historical data trend for Pentixapharm Holding AG's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pentixapharm Holding AG Current Accrued Expense Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
- - - -

Pentixapharm Holding AG Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24
Current Accrued Expense Get a 7-Day Free Trial - - - - -

Pentixapharm Holding AG Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Pentixapharm Holding AG Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Pentixapharm Holding AG's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Pentixapharm Holding AG Business Description

Traded in Other Exchanges
Address
Robert-Rossle-Street 10, Berlin, DEU
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Headlines

No Headlines